Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies for oncogene amplified cancers through the study of extrachromosomal DNA (ecDNA) [2] Group 1: Company Overview - Boundless Bio is dedicated to addressing the unmet needs of patients with oncogene amplified tumors, which are linked to ecDNA observed in 14% to 17% of cancer patients [2] - The company is developing ecDNA-directed therapeutic candidates, including BBI-355, a selective CHK1 inhibitor, and BBI-825, a selective RNR inhibitor [2] - Boundless Bio is conducting a phase 1/2 clinical trial named POTENTIATE to evaluate the combination of BBI-355 and BBI-825 in patients with oncogene amplified cancers [2] Group 2: Upcoming Presentation - Boundless Bio will present a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from October 22-26, 2025, in Boston, MA [1] - The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355 targeting unique dependencies of oncogene amplified cancers [1] - The poster session is scheduled for October 23, 2025, from 12:30 PM to 4:00 PM ET, located at Level 2, Exhibit Hall D [1]